Kampmann Melissa S. Has $2.59 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Kampmann Melissa S. cut its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 19.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 33,335 shares of the medical device company's stock after selling 7,905 shares during the period. DexCom comprises approximately 2.0% of Kampmann Melissa S.'s holdings, making the stock its 27th biggest position. Kampmann Melissa S.'s holdings in DexCom were worth $2,592,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of DXCM. Empowered Funds LLC increased its position in DexCom by 6.1% in the third quarter. Empowered Funds LLC now owns 5,847 shares of the medical device company's stock worth $392,000 after buying an additional 335 shares during the period. Mutual of America Capital Management LLC grew its position in shares of DexCom by 3.8% during the third quarter. Mutual of America Capital Management LLC now owns 57,138 shares of the medical device company's stock worth $3,831,000 after acquiring an additional 2,084 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of DexCom by 44.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 314,102 shares of the medical device company's stock worth $21,058,000 after acquiring an additional 96,274 shares during the period. Swiss National Bank lifted its position in DexCom by 3.4% in the 3rd quarter. Swiss National Bank now owns 1,180,400 shares of the medical device company's stock valued at $79,134,000 after purchasing an additional 39,000 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC boosted its stake in DexCom by 305.4% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 29,646 shares of the medical device company's stock valued at $1,987,000 after purchasing an additional 22,334 shares during the period. Institutional investors own 97.75% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DXCM shares. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and lifted their target price for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup increased their price target on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a research note on Tuesday, March 4th. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Finally, Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Friday, February 14th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, DexCom has an average rating of "Moderate Buy" and a consensus target price of $99.82.

DexCom Price Performance

Shares of NASDAQ DXCM traded up $1.52 during trading on Monday, hitting $75.32. The company had a trading volume of 2,688,740 shares, compared to its average volume of 3,917,473. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The business's 50-day moving average is $83.33 and its 200 day moving average is $77.03. The company has a market cap of $29.43 billion, a P/E ratio of 52.67, a PEG ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the firm's stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company's stock, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 105,009 shares of company stock worth $8,044,178. Company insiders own 0.30% of the company's stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.